It is estimated that almost 30 million Americans suffer from migraine attacks that a lot of which are seriously affected they can hardly perform their daily tasks. Most people suffering from migraine know just how depressing the condition is. They suffer not only unbearable headaches but also nausea and vomiting, sensitivity to sound and light, and lightheadedness. To some, the symptoms would even take days to last. Sometimes, people with this condition would seek and isolate themselves in a dark room for comfort.
Indeed it is a fact there are many medications offered in the market for migraine treatment, but it is also a clear indisputable fact that curing such or seeking for a cure of one is a difficult struggle.
But hope is now around the corner as with the help of science, a new class of medications were introduced which proved to be a promising remedy for severe headaches.
In trial, a novel class of drugs, named calcitonin-gene-related peptide (CGRP) monoclonal antibodies, may be one of the few hopes in beating off migraines with few side effects.
In small conducted studies, it was reported that half of the patients treated presented a 50 % decline in migraine occurrences.
It is as well assessed that about one third of the population who experience migraines could benefit from preemptive measure or treatment; these medications are said to be taken once in a month via injection.
It may take years before they become available to the public, but specialists are confident to confirm these would be the first class of anti-migraine drugs to hit the marketplace since 1991.